Dermatology & Medspa Biologics Distributor in Columbus, GA

How medspas and dermatology practices typically evaluate a new vendor

A medical spa's purchasing decision usually runs through the supervising physician, since medspas operate under physician supervision by definition, while dermatology and plastic surgery practices tend to route a new biologics vendor through whoever already manages their existing injectable or topical product lines.

In either case, the review centers on documentation: processing description, donor eligibility summary, and certificate of analysis, rather than marketing claims.

Practices that already keep a vendor file for other product categories can usually extend that same file structure to a biologics distributor without building a new process.

Opening a verified account

Accounts require NPI verification before any pricing or ordering access is granted, since these products are limited to licensed physicians and to medspas, dermatology, and plastic surgery practices operating under appropriate physician supervision.

After verification, a practice can schedule a physician-level conversation about documentation and request the full ingredient disclosure available for exosome products.

Logistics for shipments into the region

Cryopreserved products ship overnight on dry ice in validated containers and require -80 degree Celsius storage on arrival; lyophilized exosome and Wharton's jelly formats are described by the supplier as shelf-stable and are handled per the insert supplied with that lot.

Lot identifiers should be logged at the patient record level so a practice in Columbus can trace any product back to its specific donor lot and documentation.

Confirming fit before adopting a new product line

Neither the Wharton's jelly products nor the exosome products carry FDA approval for any disease or condition, and the supplier does not advise on clinical use, indications, or protocols.

A practice should confirm the regulatory posture of any intended use with the Georgia Composite Medical Board's requirements and its own legal counsel before adding a new biologics line to its offerings.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.